Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson’s Disease
Discover the webinar with OPM Management :
Discover the April 2, 2025 interview with Karine Lignel on the Journal des Biotechs!
An opportunity to review OPM’s development strategy and the latest news linked to the submission of the protocol for its Phase 1b/2a REVERT clinical trial with OPM-101!
To find out more, click here
Webinar | Phase 1b/2a Study REVERT |
Discover the webinar (in french) 1 April 2025 !
Webinar | The development strategy in targeted radiotherapy |
Discover the webinar (in french) 25 June 2024 !
Discover OPM’s posters!
ESMO 2025:
Authors : MICHIELIN Olivier, MD Hôpitaux Universitaires de Genève; Bruno ROBIN, Pharm.D. ; Maria Eugenia RIVEIRO, PhD ; Jan HOFLACK, PhD ; Philippe GENNE, PhD Oncodesign Precision Medicine
UEG Week 2024:
Authors : L Peyrin-Biroulet, M.D., PhD IHU INFINY – CHRU de NANCY, France; B. Robin Pharm.D, J. Hoflack, PhD, P. Genne, PhD – Oncodesign Precision Medicine, Dijon, France
AACR 2024:
- “Unlocking the Potential of OPM-383: A Novel LRRK2 Inhibitor in Cancer Therapy”
Authors: Maria Eugenia Riveiro, Petra Blom, Kenji Shoji, Jan Hoflack
Oncodesign Precision Medicine S.A., Dijon, France - “OPM-116, a highly potent and specific PI3Kγ inhibitor to enhance antitumor immunity”
Authors: Kenji F. Shoji, Oleksandr Levenets, Petra Blom, Maria Eugenia Riveiro, Jan Hoflack
Oncodesign Precision Medicine S.A., Dijon, France
IBD 2024 :
- “Unveiling the strong safety profile and high target engagement of OPM-101, a first-in-class orally available RIPK2 Inhibitor, in healthy volunteers, a Phase 1 Clinical trial “
Authors: ROBIN Bruno, Pharm.D. – HOFLACK Jan, PhD. – GENNE Philippe, PhD.
Oncodesign Precision Medicine S.A., Dijon, France